Here's What You May Have Missed About HALO

Halozyme Therapeutics marked a 5.3% change this morning, compared to -0.4% for the S&P 500. Is it a good value at today's price of $48.24? Only an in-depth analysis can answer that question, but here are some facts that can give you an idea:

  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally.

  • Halozyme Therapeutics belongs to the Healthcare sector, which has an average price to earnings (P/E) ratio of 13.21 and an average price to book (P/B) of 4.07

  • The company's P/B ratio is 22.7

  • Halozyme Therapeutics has a trailing 12 month Price to Earnings (P/E) ratio of 19.5 based on its trailing 12 month price to earnings (Eps) of $2.47 per share

  • Its forward P/E ratio is 16.0, based on its forward earnings per share (Eps) of $3.01

  • HALO has a Price to Earnings Growth (PEG) ratio of 0.72, which shows the company is very undervalued compared to its earnings growth estimates.

  • Over the last four years, Halozyme Therapeutics has averaged free cash flows of $51,826,750.00, which on average grew 185.6%

  • HALO's gross profit margins have averaged 36.0 % over the last four years and during this time they had a growth rate of 511.5 % and a coefficient of variability of 117.2 %.

  • Halozyme Therapeutics has moved 20.0% over the last year compared to -17.6% for the S&P 500 -- a difference of 37.7%

  • HALO has an average analyst rating of buy and is -2.12% away from its mean target price of $49.29 per share

At Market Interference, our mission is to give investors access to timely and accurate data to help them make better investment decisions. subscribe to our free newsletter today to keep track of each day's market movers!

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.